Table 7.
Association between Sponsor and clinical outcomes: Growth
| |
|
Assessment of outcome |
|
|
|
|---|---|---|---|---|---|
|
Growth |
Source of funding |
Positive* |
Neutral* |
Chi-square p value |
Fisher’s exact p value |
| n (%) $$ | n (%) $$ | ||||
| Weight gain N = 56 |
Industry |
2 (3.6) |
35 (62.5) |
0.309 |
0.266 |
| |
None/Not clear |
2 (3.6) |
10 (17.9) |
|
|
| |
Non industry |
0 |
7 (12.5) |
|
|
| Length gain N = 40 |
Industry |
3 (7.5) |
29 (72.5) |
0.667 |
1.00 |
| |
None/Not clear |
|
6 (15) |
|
|
| |
Non industry |
|
2 (5) |
|
|
| Head Circumference N = 31 |
Industry |
4 (12.9) |
23 (74.2) |
0.712 |
1.00 |
| |
None /Not clear |
|
3 (9.7) |
|
|
| Non industry | 1 (3.2) | ||||
$$Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.